Kaleido Biosciences is a clinical-stage healthcare company focused on pioneering the development of novel microbiome metabolic therapies. The company's proprietary Microbiome Metabolic Therapy (MMT) platform leverages the unique ability of the microbiome to impact human health and treat a variety of diseases. By targeting metabolic pathways, Kaleido aims to develop interventions that can alter microbial environments to effect positive health outcomes. As of the latest update, their website at https://kaleido.com/ provides comprehensive information about their therapeutic approaches, ongoing clinical trials, and potential impact on diverse therapeutic areas.